Bristol Myers Squibb (CELG-RI) Dividend Coverage Ratio Growth (1y) (2010 - 2026)
Powered by 
Analysis
Bristol Myers Squibb (CELG-RI) Dividend Coverage Ratio Growth (1y) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Div. Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.84 Bn | 621.08 Bn | 17.26 Bn | -3.09% |
| 2 | AbbVie | 446.83 Bn | 440.26 Bn | 12.70 Bn | 264.24% |
| 3 | Merck | 357.75 Bn | 350.61 Bn | 12.21 Bn | -129.25% |
| 4 | Novartis Ag | 267.56 Bn | 259.87 Bn | 11.24 Bn | -30.09% |
| 5 | Pfizer | 156.74 Bn | 145.04 Bn | 10.94 Bn | -108.11% |
| 6 | Sanofi | 52.18 Bn | 44.80 Bn | 10.79 Bn | -92.21% |
| 7 | Revolution Medicines | 43.15 Bn | 43.15 Bn | - | - |
| 8 | Incyte | 24.65 Bn | 20.11 Bn | 1.57 Bn | - |
| 9 | United Therapeutics | 21.30 Bn | 18.63 Bn | 683.80 Mn | - |
| 10 | Bristol Myers Squibb | 232.18 Mn | -10.83 Bn | 9.25 Bn | 147.65% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 147.65% |
| Mar 31, 2026 | 6.69% |
| Dec 31, 2025 | 1,279.13% |
| Sep 30, 2025 | 73.94% |
| Jun 30, 2025 | -24.81% |
| Mar 31, 2025 | 119.92% |
| Dec 31, 2024 | -95.89% |
| Sep 30, 2024 | -38.47% |
| Jun 30, 2024 | -20.25% |
| Mar 31, 2024 | -618.34% |
| Dec 31, 2023 | -14.11% |
| Sep 30, 2023 | 16.54% |
| Jun 30, 2023 | -98.54% |
| Mar 31, 2023 | 75.07% |
| Dec 31, 2022 | -18.06% |
| Sep 30, 2022 | -2.14% |
| Jun 30, 2022 | -10.21% |
| Mar 31, 2022 | -40.88% |
| Dec 31, 2021 | 121.98% |
| Sep 30, 2021 | -22.97% |